Adjusted significance levels for subgroup analyses in clinical trials.
about
Subgroup analyses in confirmatory clinical trials: time to be specific about their purposesMethods for identification and confirmation of targeted subgroups in clinical trials: A systematic reviewOptimizing Trial Designs for Targeted TherapiesBiomarker driven population enrichment for adaptive oncology trials with time to event endpoints.Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Integrating biomarkers in clinical trials.Adaptive designs for confirmatory clinical trials with subgroup selection.Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.Statistical controversies in clinical research: statistical significance-too much of a good thing ….Group sequential designs with prospectively planned rules for subpopulation enrichment.Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.Estimation after subpopulation selection in adaptive seamless trials.Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.Group sequential enrichment design incorporating subgroup selection.Designing Issues in Confirmatory Adaptive Population Enrichment Trials.A conditional error function approach for subgroup selection in adaptive clinical trials.Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.Futility for subgroup analyses in the adaptive signature design.Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker.Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial
P2860
Q28067390-7C55DFBB-47BB-40B5-ACA3-8C8B5B74FD25Q28086970-683FC931-0E18-4902-BE8F-81987E11BE19Q28554393-718DE9A8-95AF-40F5-BF6F-2D55272D7B12Q35226583-1A0948D2-1C6C-47A1-9916-DEF92C5EAC4BQ36133455-4B2568D6-2195-40F6-9594-4FEFB7013D83Q37731264-FE75ED19-244E-437A-84BC-A5FCEA3277FEQ37853183-AD6C7C86-A19B-47D8-9F54-E0FCB474AB1AQ38176071-84A93338-375D-4789-8420-4A76D6DDE95DQ38447119-E8619CAD-D68C-4E61-9AB7-9BB823C2F4D3Q38727877-92CE9AF8-75BD-4844-ACED-459796B818CFQ39852504-2E1EDA7C-862F-405A-9A44-4300EDA2E99AQ39993897-6EE046C4-3979-460C-A9E6-44168DBE90C1Q41027668-9828D759-EDF1-4980-B5EB-B62930B6B5E3Q43628188-594135E8-3985-482B-A0D4-ADFDB4E6404FQ44588751-9A64F472-C926-465B-ADFB-79F2D5E80E3FQ44999067-AF7AACFC-B52C-4976-B4BB-BD5D4F2B5265Q46406244-F532B170-72E7-4F3F-91CF-726E8E97A693Q47172414-DDBB301F-2F6B-4B40-AB79-2725A6C32DEEQ48229380-BD7B9630-3F9C-446A-B2EE-0F5EAC080585Q51026685-96C5A57D-D176-42A1-B19A-1BC80156A0ADQ58575535-7000F7DF-DBA4-4A33-AABC-EBA1D280D4FC
P2860
Adjusted significance levels for subgroup analyses in clinical trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Adjusted significance levels for subgroup analyses in clinical trials.
@en
Adjusted significance levels for subgroup analyses in clinical trials.
@nl
type
label
Adjusted significance levels for subgroup analyses in clinical trials.
@en
Adjusted significance levels for subgroup analyses in clinical trials.
@nl
prefLabel
Adjusted significance levels for subgroup analyses in clinical trials.
@en
Adjusted significance levels for subgroup analyses in clinical trials.
@nl
P1476
Adjusted significance levels for subgroup analyses in clinical trials.
@en
P2093
Bart Spiessens
Muriel Debois
P304
P356
10.1016/J.CCT.2010.08.011
P407
P577
2010-09-09T00:00:00Z